GlobeNewswire Inc. · Aug 11, 2022
Brickell Biotech Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Phase 1 study of BBI-02 progressing well and expect to initiate MAD part of the study next month
NASDAQ · BBI
Brickell Biotech, Inc.
Healthcare · Biotechnology
$2.35
Up+$0.05 (+2.17%)
Updated Sep 11, 2026, 7:14 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 7.08M
- P/E ratio
- -0.97
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 31.32K
- Avg. volume
- 325.65K
Price performance
BBI price history
1M range · 0 trading sessions · Daily adjusted prices
BBI does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest BBI news
The latest Smart Investors Daily articles mentioning BBI.
Stock researchCompany · Overview
BBI research
Overview
Company profile and research snapshot.
Company profile
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 16, 2022 | HC Wainwright & Co. | Buy | — |
| May 13, 2022 | Lake Street | Hold | — |
| Mar 8, 2022 | William Blair | Outperform | — |
| Jan 18, 2022 | HC Wainwright & Co. | Buy | — |
| Aug 28, 2020 | Lake Street | Buy | — |
News briefing
No generated briefing is available yet.
GlobeNewswire Inc. · Aug 2, 2022
Brickell Biotech to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on August 11, 2022
BOULDER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that it will report its second quarter financial results on Thursday, August 11th. Brickell’s management will host a conference call and webcast at 4:30 p.m. EDT that same day to discuss the financial results and recent corporate highlights.
GlobeNewswire Inc. · Jul 6, 2022
Brickell Biotech to Participate at William Blair Biotech Focus Conference 2022
BOULDER, Colo., July 06, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that its management team will participate in a fireside chat at the upcoming William Blair Biotech Focus Conference 2022, being held in New York on July 12 & 13, 2022.
GlobeNewswire Inc. · Jul 1, 2022
Brickell Biotech Announces 1-For-45 Reverse Stock Split
Common stock will begin trading on a split-adjusted basis on July 5, 2022 Common stock will begin trading on a split-adjusted basis on July 5, 2022
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
